<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011371</url>
  </required_header>
  <id_info>
    <org_study_id>424-2017</org_study_id>
    <nct_id>NCT04011371</nct_id>
  </id_info>
  <brief_title>Cyanoacrylate Closure for Treatment of Venous Leg Ulcers</brief_title>
  <official_title>Cyanoacrylate Closure for Treatment of Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous leg ulcers (VLUs) are a common wound with significant morbidity and cost, and
      suboptimal therapeutic options. VLUs result from chronic venous insufficiency, including
      venous reflux and post-thrombotic syndrome. VLU can take from months to years to heal, and
      54-78% recur. Current therapies include wound, compression therapy, and medications. These
      treatments can increase the rate of healing, and reduce recurrence, however these therapies
      can be burdensome, painful, and ineffective, and despite these therapies, ~50% of wounds
      become chronic. Chronic VLUs can be painful, malodorous, and infected, and they often
      significantly limit an individual's function and mobility. An emerging therapy for
      symptomatic venous reflux is the closure of the culprit vein by endovenous closure with a
      cyanoacrylate adhesive implant. Recent studies show cyanoacrylate closure (CAC) to be a safe
      and effective treatment for varicosities resulting from symptomatic incompetent great
      saphenous veins. This study will evaluate the safety and effectiveness of CAC for VLUs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing rate</measure>
    <time_frame>3 months</time_frame>
    <description>Change in ulcer size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing rate</measure>
    <time_frame>12 months</time_frame>
    <description>Change in ulcer size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closure rate</measure>
    <time_frame>12 months</time_frame>
    <description>Time to ulcer closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life: EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire - measures patient-reported health related to five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses for each parameter are coded 1-5, with a lower score reflecting better health, and a higher score meaning worse health. Overall health is self-rated on a scale 0-100, with 0 meaning the worst and 100 meaning the best health imaginable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Cyanoacrylate closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cyanoacrylate closure</intervention_name>
    <description>Cyanoacrylate glue embolization targeting venous insufficiency</description>
    <arm_group_label>Cyanoacrylate closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years old at time of screening;

          2. Venous leg ulcer;

          3. Venous insufficiency (&gt;0.5 seconds; confirmed by Doppler within last 6 months);

          4. ABI of ≥0.9;

          5. Capable of understanding the study and providing informed consent.

        Exclusion Criteria:

          1. Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates;

          2. Acute superficial thrombophlebitis;

          3. Bilateral treatment

          4. Thrombophlebitis migrans;

          5. Deep venous thrombosis;

          6. Deep venous incompetence or occlusion in external iliac or distal veins in the
             affected extremity (as assessed based on spontaneity, phasicity, augmentation,
             pulsatility, and compressibility on ultrasound);

          7. Post-thrombotic syndrome;

          8. Acute sepsis;

          9. Coagulation disorders;

         10. Radiation or chemotherapy within 3 months of study;

         11. Pregnant or lactating females;

         12. Uncontrolled diabetes (HbA1c &gt;10%);

         13. Diabetic foot ulcers;

         14. Current use of systemic anticoagulation;

         15. Previous treatment of target vein;

         16. Tortuous veins;

         17. Current participation in another interventional study, or participation within 30 days
             prior to screening;

         18. Inability to tolerate compression, or to receive endovenous treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Kayssi, MD MSc MPH</last_name>
    <phone>416-480-6948</phone>
    <email>ahmed.kayssi@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Summers deLuca, PhD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>2593</phone_ext>
    <email>leslie.summersdeluca@sunnybrook.ca</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Callam MJ. Epidemiology of varicose veins. Br J Surg. 1994 Feb;81(2):167-73. Review.</citation>
    <PMID>8156326</PMID>
  </results_reference>
  <results_reference>
    <citation>Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology. 2001 Aug;52 Suppl 1:S5-15.</citation>
    <PMID>11510598</PMID>
  </results_reference>
  <results_reference>
    <citation>Van den Oever R, Hepp B, Debbaut B, Simon I. Socio-economic impact of chronic venous insufficiency. An underestimated public health problem. Int Angiol. 1998 Sep;17(3):161-7.</citation>
    <PMID>9821029</PMID>
  </results_reference>
  <results_reference>
    <citation>Abbade LP, Lastória S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005 Jun;44(6):449-56. Review.</citation>
    <PMID>15941430</PMID>
  </results_reference>
  <results_reference>
    <citation>Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999;4(1):1-7.</citation>
    <PMID>10355863</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer W, Jochmann W, Partsch H. [Varicose ulcer: healing in conservative therapy. A prospective study]. Wien Med Wochenschr. 1994;144(10-11):250-2. German.</citation>
    <PMID>7856198</PMID>
  </results_reference>
  <results_reference>
    <citation>Bergqvist D, Lindholm C, Nelzén O. Chronic leg ulcers: the impact of venous disease. J Vasc Surg. 1999 Apr;29(4):752-5.</citation>
    <PMID>10194512</PMID>
  </results_reference>
  <results_reference>
    <citation>Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health. 1999 Mar;53(3):149-53.</citation>
    <PMID>10396491</PMID>
  </results_reference>
  <results_reference>
    <citation>Lazarus GS, Cooper DM, Knighton DR, Percoraro RE, Rodeheaver G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of healing. Wound Repair Regen. 1994 Jul;2(3):165-70.</citation>
    <PMID>17156107</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelechi TJ, Johnson JJ, Yates S. Chronic venous disease and venous leg ulcers: An evidence-based update. J Vasc Nurs. 2015 Jun;33(2):36-46. doi: 10.1016/j.jvn.2015.01.003. Review.</citation>
    <PMID>26025146</PMID>
  </results_reference>
  <results_reference>
    <citation>Morrison N, Gibson K, McEnroe S, Goldman M, King T, Weiss R, Cher D, Jones A. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015 Apr;61(4):985-94. doi: 10.1016/j.jvs.2014.11.071. Epub 2015 Jan 31.</citation>
    <PMID>25650040</PMID>
  </results_reference>
  <results_reference>
    <citation>Almeida JI, Javier JJ, Mackay E, Bautista C, Proebstle TM. First human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2013 Apr;1(2):174-80. doi: 10.1016/j.jvsv.2012.09.010. Epub 2012 Dec 22.</citation>
    <PMID>26992340</PMID>
  </results_reference>
  <results_reference>
    <citation>Proebstle TM, Alm J, Dimitri S, Rasmussen L, Whiteley M, Lawson J, Davies A. Twelve-Month Follow-up of the European Multicenter Study on Cyanoacrylate Embolization of Incompetent Great Saphenous Veins. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):105-6. doi: 10.1016/j.jvsv.2013.10.009. Epub 2013 Dec 12.</citation>
    <PMID>26992985</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

